Principal Director, Surgical Oncology, BLK-Max Super Speciality Hospital, New Delhi
Part 12 of 12 in Recent Trends in Surgical Oncology - Breast and GI Oncology
Fellowship and Observership Pathways in Surgical Oncology at BLK-Max
September 6, 2026
Fellowship and observership access came up as a practical, recurring question from African doctors: what does it take to train under Dr. Jain's team at BLK-Max, and does a candidate need to already be a surgeon?
Fellowship vs observership
BLK-Max runs fellowships in surgical oncology across sub-specialties, including head and neck, breast, gastrointestinal and gynaecological oncology, and a fellowship candidate must be a postgraduate in the relevant discipline, though not necessarily a surgeon. A plain MBBS doctor without a postgraduate qualification cannot join as a fellow, but can come as an observer for one or two months, rotating through the different departments of oncology to build a working understanding of how cases are managed.
Access and cost
On whether fees for doctors coming through the Jivo Doctor Network could be waived, Dr. Jain was candid that this is an administrative decision above his authority to commit to alone, but said he personally supports it and would raise it with BLK-Max's international team. Interested doctors were directed to follow up with the Jivo team directly to get the specific process for arranging an observership or fellowship.
This article is based on a Jivo Masterclass session conducted by Dr. Rajesh Kumar Jain, Principal Director, Surgical Oncology, BLK-Max Cancer Centre, New Delhi. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording
Interested in a fellowship or observership at BLK-Max Cancer Centre? Get in touch with the Jivo team
This guide is based on a live Jivo Masterclass: Dr. Rajesh Kumar Jain taught doctors across Africa on September 6, 2026.
FROM THE LIVE Q&A
Moderator
A question from Dr. Innocent Nzili in Kenya: why do some dormant cancer cells survive initial treatment and hide in the body for years before suddenly reactivating to cause a deadly recurrence?
Dr. Rajesh Kumar Jain
The exact mechanism is still not fully known. But one clear factor is genetic aberrations that occur over time because of environmental exposure: if a patient achieves a cure but resumes alcohol or smoking, the damage caused by tobacco or other carcinogens affects the DNA again and dormant cells can get reactivated. That is one reason recurrence happens, though most of the time the actual mechanism is not known.
Book a Consultation with Dr. Rajesh Kumar Jain
Book on WhatsAppOr message us on WhatsApp: +91 98182 98669
Frequently Asked Questions
In sub-Saharan Africa, most countries do not have a PET-CT scanner. What alternatives can a doctor use to get a near-accurate estimation of disease stage without one?▼
For bone metastasis, use a nuclear bone scan; if that is unavailable, do a skeletal survey, plain X-rays of the spine, ribs, pelvis and limbs. For liver metastasis, a CT abdomen substitutes for PET, and an ultrasound is a fair investigation if CT is also unavailable. For the lungs, a CT chest is the alternative, and a plain chest X-ray is fair enough if CT is not available. Also check the uterus and ovaries with a pelvis ultrasound in every breast cancer patient, to rule out Krukenberg tumours. Ultrasound and X-rays are available almost everywhere in the world, and while less precise than PET-CT, this combination is enough to establish metastatic staging.
Many cancer cases referred from outside India are far advanced by the time they reach surgical oncology, with the objective becoming palliative rather than curative. How can doctors be made more aware of the need for timely referral?▼
Diagnosing cancer early, at stage 1 or 2, translates into cure; stage 4 offers very minimal chances of cure for any cancer. Where facilities and education are limited, the solution has three parts: awareness, awareness, and awareness, among doctors, the public and government. Over almost 30 years of practice, running thousands of community cancer-awareness camps across India, Nepal, Bhutan and Bangladesh with NGO partners has produced a real shift: around 1997, 75-80% of patients presented in stage 3 or 4; today in metropolitan India, around 60% present at an early stage.
Beyond breast cancer, where awareness is already relatively good, when should a general practitioner without easy access to specialists suspect cancers like liver, gastric or lung cancer?▼
A non-healing mouth ulcer of 15-20 days in a smoker warrants a biopsy for oral cancer. A voice change over six weeks or dysphagia should raise suspicion. A cough not responding to 4-5 weeks of anti-tuberculosis treatment needs a chest X-ray. Early satiety, feeling full after a much smaller meal than usual, is a classic warning sign for stomach cancer. Unexplained weight loss or easy fatiguability should raise suspicion of pancreatic or liver cancer, and every jaundice patient should get at least an ultrasound rather than being assumed to have hepatitis. A change in bowel habit should prompt investigation for colorectal cancer, and around 30% of bleeding per rectum, usually assumed to be piles, is actually cancer. A painless testicular swelling should not be assumed to be a hydrocele without an ultrasound, and an enlarging soft tissue lump assumed to be a lipoma should get an FNAC to rule out sarcoma.
A patient case from Dr. Alem in Ethiopia: right breast masses, two in number near the periareolar region, 3cm and 4cm, attached to each other by fibrous tissue, with core needle biopsy showing invasive ductal carcinoma. How should this proceed, and is breast conservation surgery possible?▼
Complete staging first, chest X-ray, abdominal ultrasound and a skeletal survey or bone scan, to know whether there is metastasis. If there is no distant metastasis and ER/PR is positive, go for surgery, but because this is periareolar, central-quadrant disease, mastectomy with axillary clearance is the better option over breast conservation, even if the rest of the breast looks normal on mammography. If metastasis is found instead, start with chemotherapy.
A question from Dr. Isaya Mhando in Tanzania, based on a patient seen five years ago: what are the causes of bloody discharge from the breast, with no breast lump and no palpable lymph nodes?▼
There are three common causes. Duct papilloma is the most common, a benign lesion that can sometimes transform into papillary carcinoma; ultrasound will show the ducts, and if a papilloma is found, a microdochectomy (removal of the duct under image guidance) is done and sent for histopathology. Invasive ductal carcinoma itself is the second cause; around 10% of breast cancer patients present with nipple discharge, sometimes without any lump. The third is duct ectasia, seen in perimenopausal women around 45-57 years old, usually with brownish discharge, treated the same way with a microdochectomy.
Who can apply for a surgical oncology fellowship at BLK-Max?▼
A postgraduate in the relevant discipline (not necessarily a surgeon). BLK-Max runs fellowships across sub-specialties including head and neck, breast, GI and gynaecological oncology.
Can a doctor without a postgraduate qualification train at BLK-Max?▼
Yes, as an observer for one or two months, rotating through the different oncology departments, though not as a fellow.
In This Series: Recent Trends in Surgical Oncology - Breast and GI Oncology
- 1.Recent Trends in Surgical Oncology
- 2.Breast Cancer Diagnosis, Staging and Molecular Workup
- 3.Breast Cancer Treatment: From Early-Stage to Metastatic and Oligometastatic Disease
- 4.Breast Cancer Surgery: Conservation vs Mastectomy and Axillary Management
- 5.Staging Cancer Without a PET-CT: Practical Alternatives for Resource-Limited Settings
- 6.Organ-by-Organ Red Flag Symptoms for Early Cancer Detection
- 7.Timely Referral and Awareness: Closing the Gap Between Early and Late-Stage Diagnosis
- 8.Case Discussion: Bilateral Periareolar Breast Masses and Bloody Nipple Discharge
- 9.Multidisciplinary Cancer Care: Tumour Boards, Robotic Surgery and Patient Outcomes
- 10.Circulating Tumour DNA and the Biology of Cancer Recurrence
- 11.Personalised Cancer Treatment, Immunotherapy and CAR-T Cell Therapy
- 12.Fellowship and Observership Pathways in Surgical Oncology at BLK-Max